Cargando…

Which treatment modality should we choose for advanced hepatocellular carcinoma?

Detalles Bibliográficos
Autor principal:	Kim, Do Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association for the Study of the Liver 2010
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304607/ https://www.ncbi.nlm.nih.gov/pubmed/21415577 http://dx.doi.org/10.3350/kjhep.2010.16.4.353

Ejemplares similares

Surgical radiofrequency ablation of atrial flutter: which operation should we choose?
por: Chen, Fengjie, et al.
Publicado: (2021)

Atezolizumab plus bevacizumab and tremelimumab plus durvalumab: how should we choose these two immunotherapy regimens for advanced hepatocellular carcinoma?
por: Hatanaka, Takeshi, et al.
Publicado: (2022)

Hepatocellular carcinoma and metabolic syndrome: The times are changing and so should we
por: Tsoulfas, Georgios
Publicado: (2019)

Which Fecal Immunochemical Test Should I Choose?
por: Daly, Jeanette M., et al.
Publicado: (2017)

The practicality of different eGFR equations in centenarians and near-centenarians: which equation should we choose?
por: Han, Qiuxia, et al.
Publicado: (2020)

What should medical students do to choose their specialty?
por: Aboshady, Omar Ali, et al.
Publicado: (2015)

Effect of different surgical modalities on swallowing-related quality of life in patients with glottic laryngeal squamous cell carcinoma: how should we choose?
por: Shao, Na, et al.
Publicado: (2023)

Why should you choose to publish in the Libyan Journal of Medicine?
por: Bredan, Amin, et al.
Publicado: (2016)

Can metronomic chemotherapy be an alternative to sorafenib in advanced hepatocellular carcinoma?
por: Kim, Do Young
Publicado: (2017)

Retrospective accuracy analysis of MRI based lesion size measurement in neuroblastic tumors: which sequence should we choose?
por: Gassenmaier, Sebastian, et al.
Publicado: (2020)

Hypertensive intracerebral hemorrhage: Which one should we choose between laser navigation and 3D navigation mold?
por: Yuan, Zhengbo, et al.
Publicado: (2023)

A plethora of techniques to detect mutations: Which one to choose?
por: Ghosh, K., et al.
Publicado: (2008)

All for one, but not one for all <Guideline needed; which and when should we use>
por: Notomi, Yuichi
Publicado: (2012)

Diagnosis of hepatocellular carcinoma: Which MRI contrast agent? Which diagnostic criteria?
por: Kim, So Yeon
Publicado: (2020)

What is your diagnosis and which treatment modality should be chosen for this patient?
por: Koza, Yavuzer, et al.
Publicado: (2016)

Editorial – The future depends on how we choose to behave
por: Mace, Ruth
Publicado: (2020)

A Discussion on Different Approaches for Prescribing Physical Interventions – Four Roads Lead to Rome, but Which One Should We Choose?
por: Herold, Fabian, et al.
Publicado: (2020)

Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC?
por: Negri, Francesca, et al.
Publicado: (2021)

Which criteria should we use to end isolation in hemodialysis patients with COVID-19?
por: Alfano, Gaetano, et al.
Publicado: (2022)

Choose Ye Which
por: Pratt, Ben. H.
Publicado: (1877)

Which first-generation antipsychotics should be “repurposed” for the treatment of schizophrenia
por: Leucht, Stefan, et al.
Publicado: (2022)

Treatment strategies in patients with diabetes and three‐vessel coronary disease: What should we choose?
por: Liang, Bo, et al.
Publicado: (2021)

How Should We Assign Large Infiltrative Hepatocellular Carcinomas for Staging?
por: Lee, Yoo Jin, et al.
Publicado: (2020)

Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma
por: Personeni, Nicola, et al.
Publicado: (2020)

Recent Advancements for the Treatment of Hepatocellular Carcinoma
por: Nouso, Kazuhiro
Publicado: (2023)

We or I, Which?
Publicado: (1879)

What’s to Lose When We Choose: Decision-making in Lung Transplantation
por: Toporek, Alexandra H., et al.
Publicado: (2023)

Please provide us with a reasonable definition for curative R0 resection in Barrett’s esophagus neoplasia; which one should we choose?
por: Pioche, Mathieu, et al.
Publicado: (2015)

A Growing Evil Which Should Be Remedied
Publicado: (1892)

Should We Be Permissive with Hypercapnia?
por: Nassar, Boulos
Publicado: (2022)

What Should We Eat?
Publicado: (1909)

Men's Health: What Should We Know?
por: Kim, Sae Woong
Publicado: (2015)

Outcome of Initial Progression During Nivolumab Treatment for Hepatocellular Carcinoma: Should We Use iRECIST?
por: Lee, Dong Ho, et al.
Publicado: (2021)

Aging with Disability: What Should We Pay Attention to?
por: Lim, Jae-Young
Publicado: (2022)

Obesity inducing acute respiratory distress syndrome: we should choose the right population!
por: Honore, Patrick M., et al.
Publicado: (2019)

Macrotrabecular-Massive Hepatocellular Carcinoma: What Should We Know?
por: Li, Xiaoming, et al.
Publicado: (2022)

Liver transplantation in hepatocellular carcinoma – should we perform downstaging?
por: Filipec Kanižaj, Tajana, et al.
Publicado: (2022)

Choose the right treatment for the right patients
por: Sheu, Shwu-Jiuan
Publicado: (2015)

Should we change the treatment plan in early hepatocellular carcinoma with chronic kidney disease?
por: Chao, Wu-Po, et al.
Publicado: (2023)

A RESPONSIBILITY THAT WE SHOULD NOT SHIRK
por: Kuruvilla, K.
Publicado: (1995)

Cannot write session to /tmp/vufind_sessions/sess_vph7ksjg1vvh80edjpjbk01lfm